Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

医学 转移性尿路上皮癌 无容量 养生 内科学 临床终点 肿瘤科 实体瘤疗效评价标准 化疗 临床试验 进行性疾病 癌 临床研究阶段 泌尿科 尿路上皮癌 外科 免疫疗法 膀胱癌 癌症
作者
Padmanee Sharma,Margitta Retz,Arlene O. Siefker‐Radtke,Ari David Baron,Andrea Necchi,Jens Bedke,Elizabeth R. Plimack,Daniel A. Vaena,Marc‐Oliver Grimm,Sergio Bracarda,José Ángel Arranz,Sumanta K. Pal,Chikara Οhyama,Abdel Saci,Xiaotao Qu,Alexandre Lambert,Suba Krishnan,Alex Azrilevich,Matthew D. Galsky
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:18 (3): 312-322 被引量:1740
标识
DOI:10.1016/s1470-2045(17)30065-7
摘要

Patients with metastatic urothelial carcinoma have a dismal prognosis and few treatment options after first-line chemotherapy. Responses to second-line treatment are uncommon. We assessed nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for safety and activity in patients with metastatic or surgically unresectable urothelial carcinoma whose disease progressed or recurred despite previous treatment with at least one platinum-based chemotherapy regimen.In this multicentre, phase 2, single-arm study, patients aged 18 years or older with metastatic or surgically unresectable locally advanced urothelial carcinoma, measurable disease (according to Response Evaluation Criteria In Solid Tumors v1.1), Eastern Cooperative Oncology Group performance statuses of 0 or 1, and available tumour samples for biomarker analysis received nivolumab 3 mg/kg intravenously every 2 weeks until disease progression and clinical deterioration, unacceptable toxicity, or other protocol-defined reasons. The primary endpoint was overall objective response confirmed by blinded independent review committee in all treated patients and by tumour PD-L1 expression (≥5% and ≥1%). This trial is registered with ClinicalTrials.gov, number NCT02387996, and is completed. Follow-up is still ongoing.Between March 9, 2015, and Oct 16, 2015, 270 patients from 63 sites in 11 countries received nivolumab, and 265 were evaluated for activity. Median follow-up for overall survival was 7·00 months (IQR 2·96-8·77). Confirmed objective response was achieved in 52 (19·6%, 95% CI 15·0-24·9) of 265 patients. Confirmed objective response was achieved in 23 (28·4%, 95% CI 18·9-39·5) of the 81 patients with PD-L1 expression of 5% or greater, 29 (23·8%, 95% CI 16·5-32·3) of the 122 patients with PD-L1 expression of 1% or greater, and 23 (16·1%, 95% CI 10·5-23·1) of the 143 patients with PD-L1 expression of less than 1%. Grade 3-4 treatment-related adverse events occurred in 48 (18%) of 270 patients-most commonly grade 3 fatigue and diarrhoea, which each occurred in five patients. Three deaths were attributed to treatment (pneumonitis, acute respiratory failure, and cardiovascular failure).Nivolumab monotherapy provided meaningful clinical benefit, irrespective of PD-L1 expression, and was associated with an acceptable safety profile in previously treated patients with metastatic or surgically unresectable urothelial carcinoma.Bristol-Myers Squibb.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
lllll1243发布了新的文献求助10
刚刚
www完成签到,获得积分20
刚刚
矿泉水完成签到,获得积分10
刚刚
syvshc的应助被WUHAO采纳,获得10
刚刚
刚刚
1秒前
1秒前
yuan完成签到,获得积分10
1秒前
WangJ1018发布了新的文献求助10
1秒前
啊森完成签到 ,获得积分10
1秒前
1秒前
2秒前
3秒前
新楚完成签到 ,获得积分10
3秒前
科研通AI6.3的应助被开心德地采纳,获得10
4秒前
Drcai发布了新的文献求助10
4秒前
搞怪的老九的应助被荔枝采纳,获得10
4秒前
水煮电吹风的应助被荔枝采纳,获得10
4秒前
烊烊烊发布了新的文献求助10
5秒前
禾页完成签到,获得积分10
5秒前
6秒前
水牛完成签到,获得积分10
6秒前
小羊发布了新的文献求助10
6秒前
大个的应助被ubless607采纳,获得30
6秒前
动物园小科畜完成签到,获得积分10
6秒前
852的应助被小羊爱科研采纳,获得10
6秒前
bkagyin的应助被漂泊采纳,获得10
7秒前
zzc完成签到,获得积分10
7秒前
7秒前
7秒前
刘锰发布了新的文献求助10
8秒前
香蕉觅云的应助被执着采纳,获得10
8秒前
8秒前
yanglikang发布了新的文献求助10
8秒前
灵巧寻芹完成签到,获得积分10
8秒前
9秒前
FashionBoy的应助被kkkk采纳,获得10
9秒前
皮卡丘发布了新的文献求助10
10秒前
zhangxu发布了新的文献求助10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187835
求助须知:如何正确求助?哪些是违规求助? 9575825
关于积分的说明 21843558
捐赠科研通 7785715
什么是DOI,文献DOI怎么找? 3435125
关于科研通互助平台的介绍 2559495
邀请新用户注册赠送积分活动 2482008